ID

45140

Beskrivning

Principal Investigator: Rex Chisholm, PhD, Northwestern University, Evanston, IL, USA MeSH: Electronic Health Records,Hematologic Diseases,Chronic Disease,Anthropometry,Lipids,Diabetic Retinopathy,Hypothyroidism https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000360 The **e**lectronic **M**edical **R**ecords and **Ge**nomics (eMERGE) Network is a consortium of five participating sites (Group Health Seattle, Marshfield Clinic, Mayo Clinic, Northwestern University, and Vanderbilt University) funded by the NHGRI to investigate the use of electronic medical record systems for genomic research. The goal of eMERGE is to conduct genome-wide association studies in approximately 19,000 individuals using EMR-derived phenotypes and DNA from linked Biorepositories. Using electronic phenotyping methods, the consortium used DNA samples from all participating sites to explore the genetic determinants of red cell indices, white blood count (WBC) differential, diabetic retinopathy, height, serum lipid levels, specifically total cholesterol, HDL (high density lipoprotein), LDL (low density lipoprotein), and triglycerides, and autoimmune hypothyroidism as well as using the phenome-wide association study (PheWAS) paradigm to replicate and discover relationships between targeted genotypes with multiple phenotypes. eMERGE led studies for which original genotyping was performed and are included in this merged set: - Genome-Wide Association Study on Cataract and HDL in the Personalized Medicine Research Project Cohort, phs000170 - Development and Use of Network Infrastructure for High-Throughput GWA Studies, phs000234 - Vanderbilt Genome-Electronic Records (VGER) Project: QRS Duration, phs000188 - Northwestern NUgene Project: Type 2 Diabetes, phs000237 - A Genome-Wide Association Study of Peripheral Arterial Disease, phs000203 Sites and participants include: *Vanderbilt University:* BioVU, Vanderbilt's DNA databank, is an enabling resource for exploration of the relationships among genetic variation, disease susceptibility, and variable drug responses, and represents a key first step in moving the emerging sciences of genomics and pharmacogenomics from research tools to clinical practice. BioVU acquires DNA from discarded blood samples collected from routine patient care. The biobank is linked to de-identified clinical data extracted from Vanderbilt's EMR, which forms the basis for phenotype definitions used in genotype-phenotype correlations. *Marshfield Clinic:* The Marshfield Clinic Personalized Medicine Research Project is a population-based biobank in central Wisconsin with more than 20,000 adult subjects who provided written, informed consent to access their medical records and provided a blood sample from which DNA was extracted and plasma and serum stored. In addition to an average of 30 years of medical history data, a questionnaire about environmental exposures, including a detailed food frequency questionnaire, is available to facilitate gene/environment studies. *Northwestern University:* The NUgene Project is a repository with longitudinal medical information from participating patients at affiliated hospitals and outpatient clinics from the Northwestern University Medical Center. Participants' DNA samples are coupled with data from a self-reported questionnaire and continuously updated data from our Electronic Medical Record (EMR) representing actual clinical care events. Northwestern has a state-of-the art, comprehensive inpatient and outpatient EMR system of over 2 million patients. NUgene has broad access to participant data for all outpatient visits as well as inpatient data via a consolidated data warehouse. NUgene participants consent to distribution and use of their coded DNA samples and data for a broad range of genetic research by third-party investigators. *Group Health(GH)/University of Washington (UW):* Aging and Dementia eMERGE study biorepository leverages rich population-based longitudinal data from both electronic medical records and in-depth research data to explore genome wide associations. Participants include Seattle-area members of GH (a large integrated health care system in Washington State) consented and enrolled in 1) the UW Alzheimer's Disease Patient Registry (ADPR) and 2) the Adult Changes in Thought (ACT) study. The ADPR (PI: Eric B. Larson; NIH/NIA U01 AG 006781) is a population-based registry of incident dementia cases designed to identify all new Alzheimer's Disease cases within GH from 1987 to 1996. Medical history, physical, laboratory testing, and neuropsychological testing were performed on all consenting potential cases for determination of dementia status by a consensus conference. The study base of the ADPR population was stable with an attrition rate of less than 1%/year. The ACT study (PI: Eric B. Larson; NIH/NIA U01 AG 006781) is an ongoing community-based cohort study of aging and dementia. The original cohort of 2,581 randomly selected dementia-free members age 65 and older was enrolled in 1994-1996 and expanded by 811 in 2000-2002. Continuous enrollment to maintain a cohort of 2,000 dementia free persons began in 2005. Participants receive biennial assessment including cognitive status determination. The ACT sub-sample is stable; for the original cohort, median enrollment in GH was 19 years prior to joining the ACT study, and 85% of the cohort has ≥10 years of GH enrollment. DNA for the ADPR participants were obtained through a companion study, Genetic Differences in Cases and Controls (PI: Walter Kukull; NIH/NIA R01 AG007584). DNA obtained through both studies were extracted from blood using Gentra Systems Puregene methods. DNA concentration is determined by UV optical density. All samples are checked for quality by 260/280 ratio. For long-term storage, samples are aliquoted and stored at -70°C. *Mayo Clinic:* The Mayo biobank is a disease-specific biobank for vascular diseases including peripheral arterial disease (PAD). PAD patients were identified from individuals referred to the non-invasive vascular laboratory for lower extremity arterial evaluation. Since 1997, laboratory findings have been recorded into an electronic database employing an in-house software package for data archiving and retrieval; this data becomes part of the Mayo EMR. Patients referred to the center with suspected PAD undergo a comprehensive non-invasive evaluation including the ankle-brachial index (ABI) - the ratio of blood pressure measured in the upper arms divided by blood pressure measured at the ankles. Controls subjects are identified from patients referred to the Cardiovascular Health Clinic for stress ECG. The prevalence of PAD in patients with normal exercise capacity who do not have inducible ischemia on the stress ECG, was 1%. Data regarding risk factors for atherosclerosis such as diabetes, dyslipidemia, hypertension, and smoking are ascertained from the EMR.

Länk

dbGaP study =phs000360

Nyckelord

  1. 2022-10-04 2022-10-04 - Chiara Middel
  2. 2022-10-12 2022-10-12 - Adrian Schulz
Rättsinnehavare

Rex Chisholm, PhD, Northwestern University, Evanston, IL, USA

Uppladdad den

12 oktober 2022

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :


Inga kommentarer

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

dbGaP phs000360 eMERGE Network Combined Dataset

Eligibility Criteria

Inclusion and exclusion criteria
Beskrivning

Inclusion and exclusion criteria

Subjects were determined using electronic algorithms deployed with an existing EMR.
Beskrivning

Elig.phs000360.v3.p1.1

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C0013893
UMLS CUI [1,3]
C0013850
UMLS CUI [1,4]
C0002045
UMLS CUI [1,5]
C2362543
FOR RBC INDICES: The GWAS for a quantitative trait (e.g., RBC indices) was analyzed using the algorithm developed by Dr. Kullo to exclude RBC values affected by various medical conditions in all sites was used. (Please see additional document RBC_ESR_Algorithm.doc.)
Beskrivning

Elig.phs000360.v3.p1.2

Datatyp

boolean

Alias
UMLS CUI [1,1]
C2350277
UMLS CUI [1,2]
C0936012
UMLS CUI [1,3]
C0680251
UMLS CUI [1,4]
C0205476
UMLS CUI [1,5]
C0348080
UMLS CUI [1,6]
C0392760
UMLS CUI [1,7]
C1287262
FOR WBC INDICES: (Please see additional document WBC_Algorithm.doc)
Beskrivning

Elig.phs000360.v3.p1.3

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023508
FOR HEIGHT: (Please see additional document Height_Algorithm.doc)
Beskrivning

Elig.phs000360.v3.p1.4

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0005890
FOR LIPIDS: (Please see additional document Lipids_Algorithm.doc)
Beskrivning

Elig.phs000360.v3.p1.5

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023779
CASE/CONTROL DEFINITION FOR DIABETIC RETINOPATHY: (Please see additional document DiabeticRetinopathy_definition.doc)
Beskrivning

Elig.phs000360.v3.p1.6

Datatyp

boolean

Alias
UMLS CUI [1,1]
C3274646
UMLS CUI [1,2]
C1704788
UMLS CUI [1,3]
C0011884
CASE/CONTROL DEFINITION FOR HYPOTHYROIDISM: (Please see additional document Hypothyroidism_definition.doc)
Beskrivning

Elig.phs000360.v3.p1.7

Datatyp

boolean

Alias
UMLS CUI [1,1]
C3274646
UMLS CUI [1,2]
C1704788
UMLS CUI [1,3]
C0020676
CASE/CONTROL DEFINITION FOR NON-MELANOMA SKIN CANCER: (Please see additional document Non-melanoma skin cancer.doc)
Beskrivning

Elig.phs000360.v3.p1.8

Datatyp

boolean

Alias
UMLS CUI [1,1]
C3274646
UMLS CUI [1,2]
C1704788
UMLS CUI [1,3]
C0007114
CASE/CONTROL DEFINITION FOR ACTINIC KERATOSIS: (Please see additional document Actinic_keratosis_definition.doc)
Beskrivning

Elig.phs000360.v3.p1.9

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1704788
UMLS CUI [1,2]
C3274646
UMLS CUI [1,3]
C0022602
CASE/CONTROL DEFINITION FOR SEBORRHEIC KERATOSIS: (Please see additional document Seborrheic keratosis.doc)
Beskrivning

Elig.phs000360.v3.p1.10

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1704788
UMLS CUI [1,2]
C3274646
UMLS CUI [1,3]
C0022603

Similar models

Eligibility Criteria

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Inclusion and exclusion criteria
Elig.phs000360.v3.p1.1
Item
Subjects were determined using electronic algorithms deployed with an existing EMR.
boolean
C0681850 (UMLS CUI [1,1])
C0013893 (UMLS CUI [1,2])
C0013850 (UMLS CUI [1,3])
C0002045 (UMLS CUI [1,4])
C2362543 (UMLS CUI [1,5])
Elig.phs000360.v3.p1.2
Item
FOR RBC INDICES: The GWAS for a quantitative trait (e.g., RBC indices) was analyzed using the algorithm developed by Dr. Kullo to exclude RBC values affected by various medical conditions in all sites was used. (Please see additional document RBC_ESR_Algorithm.doc.)
boolean
C2350277 (UMLS CUI [1,1])
C0936012 (UMLS CUI [1,2])
C0680251 (UMLS CUI [1,3])
C0205476 (UMLS CUI [1,4])
C0348080 (UMLS CUI [1,5])
C0392760 (UMLS CUI [1,6])
C1287262 (UMLS CUI [1,7])
Elig.phs000360.v3.p1.3
Item
FOR WBC INDICES: (Please see additional document WBC_Algorithm.doc)
boolean
C0023508 (UMLS CUI [1,1])
Elig.phs000360.v3.p1.4
Item
FOR HEIGHT: (Please see additional document Height_Algorithm.doc)
boolean
C0005890 (UMLS CUI [1,1])
Elig.phs000360.v3.p1.5
Item
FOR LIPIDS: (Please see additional document Lipids_Algorithm.doc)
boolean
C0023779 (UMLS CUI [1,1])
Elig.phs000360.v3.p1.6
Item
CASE/CONTROL DEFINITION FOR DIABETIC RETINOPATHY: (Please see additional document DiabeticRetinopathy_definition.doc)
boolean
C3274646 (UMLS CUI [1,1])
C1704788 (UMLS CUI [1,2])
C0011884 (UMLS CUI [1,3])
Elig.phs000360.v3.p1.7
Item
CASE/CONTROL DEFINITION FOR HYPOTHYROIDISM: (Please see additional document Hypothyroidism_definition.doc)
boolean
C3274646 (UMLS CUI [1,1])
C1704788 (UMLS CUI [1,2])
C0020676 (UMLS CUI [1,3])
Elig.phs000360.v3.p1.8
Item
CASE/CONTROL DEFINITION FOR NON-MELANOMA SKIN CANCER: (Please see additional document Non-melanoma skin cancer.doc)
boolean
C3274646 (UMLS CUI [1,1])
C1704788 (UMLS CUI [1,2])
C0007114 (UMLS CUI [1,3])
Elig.phs000360.v3.p1.9
Item
CASE/CONTROL DEFINITION FOR ACTINIC KERATOSIS: (Please see additional document Actinic_keratosis_definition.doc)
boolean
C1704788 (UMLS CUI [1,1])
C3274646 (UMLS CUI [1,2])
C0022602 (UMLS CUI [1,3])
Elig.phs000360.v3.p1.10
Item
CASE/CONTROL DEFINITION FOR SEBORRHEIC KERATOSIS: (Please see additional document Seborrheic keratosis.doc)
boolean
C1704788 (UMLS CUI [1,1])
C3274646 (UMLS CUI [1,2])
C0022603 (UMLS CUI [1,3])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial